Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. by Cronin, Kenneth D et al.
UCSF
UC San Francisco Previously Published Works
Title
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-
synuclein in transgenic mouse brain.
Permalink
https://escholarship.org/uc/item/28n80199
Journal
Human molecular genetics, 18(17)
ISSN
0964-6906
Authors
Cronin, Kenneth D
Ge, Dongliang
Manninger, Paul
et al.
Publication Date
2009-09-01
DOI
10.1093/hmg/ddp265
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Expansion of the Parkinson disease-associated
SNCA-Rep1 allele upregulates human a-synuclein
in transgenic mouse brain
Kenneth D. Cronin1, Dongliang Ge1, Paul Manninger2, Colton Linnertz1, Anna Rossoshek3,
Bonnie M. Orrison3, David J. Bernard3, Omar M.A. El-Agnaf4, Michael G. Schlossmacher2,
Robert L. Nussbaum5 and Ornit Chiba-Falek1,6,
1Center for Human Genome Variation, Institute for Genome Sciences and Policy, Duke University, Durham, NC
27708, USA, 2Division of Neurosciences, Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario,
Canada K1H 8M5, 3Genetic Disease Research Branch, National Human Genome Research Institute, National
Institute of Health, Bethesda, MD 20892-4472, USA, 4Department of Biochemistry, Faculty of Medicine and Health
Sciences, United Arab Emirates University, Al Ain, UAE, 5Division of Medical Genetics, Institute for Human Genetics,
University of California, San Francisco, CA 94143, USA and 6Division of Neurology, Department of Medicine, Duke
University Medical Center, Durham, NC 27708, USA
Received March 9, 2009; Revised and Accepted June 1, 2009
a-Synuclein (SNCA) gene has been implicated in the development of rare forms of familial Parkinson disease
(PD). Recently, it was shown that an increase in SNCA copy numbers leads to elevated levels of wild-type
SNCA-mRNA and protein and is sufficient to cause early-onset, familial PD. A critical question concerning
the molecular pathogenesis of PD is what contributory role, if any, is played by the SNCA gene in sporadic
PD. The expansion of SNCA-Rep1, an upstream, polymorphic microsatellite of the SNCA gene, is associated
with elevated risk for sporadic PD. However, whether SNCA-Rep1 is the causal variant and the underlying
mechanism with which its effect is mediated by remained elusive. We report here the effects of three distinct
SNCA-Rep1 variants in the brains of 72 mice transgenic for the entire human SNCA locus. Human SNCA-
mRNA and protein levels were increased 1.7- and 1.25-fold, respectively, in homozygotes for the expanded,
PD risk-conferring allele compared with homozygotes for the shorter, protective allele. When adjusting for
the total SNCA-protein concentration (endogenous mouse and transgenic human) expressed in each
brain, the expanded risk allele contributed 2.6-fold more to the SNCA steady-state than the shorter allele.
Furthermore, targeted deletion of Rep1 resulted in the lowest human SNCA-mRNA and protein concen-
trations in murine brain. In contrast, the Rep1 effect was not observed in blood lysates from the same
mice. These results demonstrate that Rep1 regulates human SNCA expression by enhancing its transcription
in the adult nervous system and suggest that homozygosity for the expanded Rep1 allele may mimic locus
multiplication, thereby elevating PD risk.
INTRODUCTION
a-Synuclein (SNCA) (GenBank: AF163864; Ensembl:
ENSG00000145335; OMIM, Online Mendelian Inheritance
in Man: MIM 163890) gene mutations (1–3) and copy
number variations (4–8) have been implicated in the develop-
ment of rare forms of familial Parkinson disease (PD, MIM
168600). Moreover, a recent genome-wide association study
To whom correspondence should be addressed at: Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, DUMC Box
91009, Duke University, Durham, NC 27708, USA. Tel: þ1 9196818001; Fax: þ1 9196136448; Email: o.chibafalek@duke.edu
# 2009 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Human Molecular Genetics, 2009, Vol. 18, No. 17 3274–3285
doi:10.1093/hmg/ddp265
Advance Access published on June 4, 2009
provided further support for the role of SNCA in familial PD
susceptibility (9). Recently published evidence showed that
an increase in SNCA copy numbers leads to elevated levels
of wild-type (WT) SNCA protein in vivo and is sufficient to
cause early-onset, familial PD. Whereas the triplication of
the WT SNCA locus leads to 2-fold overexpression of
SNCA-mRNA and protein, duplication results in a 1.5-fold
elevation. Duplication results in lower penetrance than is
seen with triplication, a slightly later onset of the disease
and a ‘milder’ phenotype that is essentially indistinguishable
from sporadic PD (5–8,10,11). Furthermore, PD, dementia
with Lewy bodies (DLB, MIM 127750) and multiple system
atrophy (MSA) are seen as prototypes of human ‘synucleino-
pathies’, which are characterized by intracellular SNCA
inclusions. These aggregates have been identified in neuronal
Lewy bodies and neurites, two pathological hallmark lesions
of both PD and DLB (12), and in glial inclusions, a character-
istic of MSA (13). Moreover, elevated SNCA-mRNA levels
have been reported in midbrain tissue homogenates (14) and
in dopaminergic neurons from sporadic PD cases (15). These
observations emphasize the critical importance of SNCA
dosage and expression levels in the pathogenesis of PD and
related synucleinopathies.
Several association studies have demonstrated that genetic
variability across the SNCA locus, including its promoter, is
associated with altered susceptibility to sporadic PD (PDGene
database, http://www.pdgene.org/) (16–19). To date, the most
studied SNCA genetic variation is Rep1 (GenBank D4S3481),
a complex polymorphic microsatellite repeat site located
10 kb upstream of the transcription start site (20,21). The
overwhelming majority of these association studies, including
a large meta-analysis, have shown that certain alleles of
SNCA-Rep1 confer increased risk to develop late-onset, ‘idio-
pathic’ PD (22–25). Previously, we attempted to determine
whether this genetic association correlated with any biological
function. Using a reporter assay in a transiently transfected
neuronal cell culture model, we demonstrated that the
SNCA-Rep1 had a reproducible effect on regulating transcrip-
tional activity; there, certain allele lengths showed a nearly
3-fold change in expression of the reporter construct (26,27).
Given that multiplications of SNCA have been implicated in
heritable PD, where elevated dosage increases penetrance and
lowers age-of-onset, we hypothesized that a subtle increase
in SNCA expression over decades confers an elevated risk
for late-onset, sporadic PD. We posited that the strong genetic
association of SNCA-Rep1 allele expansion with PD risk
could be the consequence of a cis-acting mechanism on the
transcriptional regulation of SNCA. Moreover, it was recently
suggested that the SNCA-Rep1 genotype may also affect
SNCA protein levels in human blood samples (28).
Here, we used a transgenic mouse model to examine three
distinct Rep1 variants within the human SNCA locus to
establish the relevance of the Rep1 element in the regulation
of SNCA expression in vivo. We engineered the two most
frequent alleles that have been reported in both Caucasian
and Asian populations (22,23), i.e. the expanded,
261 bp-long Rep1 allele (68% in control whites) and its
shorter 259 bp variant (27%), into a bacterial P1 artificial
chromosome (PAC) containing the entire human SNCA
gene. We also engineered an artificial allele consisting of
a deletion of the Rep1 repeat within the same PAC. We
then compared SNCA-mRNA and protein levels in the
brain and blood specimens of transgenic mice carrying the
261 and 259 bp and the Rep1-deletion alleles in order to
compare the effect of the different alleles on the expression
of the SNCA gene in vivo.
RESULTS
Characterization of transgenic mouse lines to examine
three distinct SNCA-Rep1 genotypes
We generated transgenic mice lines for three distinct
SNCA-Rep1 genotypes carrying the 146 kb-large PAC
27M07. The PAC contains the entire human SNCA gene and
34 kb of its upstream region, including the SNCA-Rep1 site
located within 10 kb of the transcription start site (Fig. 1).
Each genotype examined contained a different allele at the
SNCA-Rep1 site. These included the two naturally occurring
variants, Rep1-261 bp and Rep1-259 bp, which carried the fol-
lowing sequence combinations, (TC)10(T)2(TC)10(TA)8(CA)11
and (TC)10(T)2(TC)10(TA)8(CA)10, respectively, and one arti-
ficial allele in which the SNCA-Rep1 repeat has been deleted
altogether, D-Rep1. Importantly, these PAC clones harbored
34 kb of non-coding DNA located upstream of exon 1,
thereby reducing possible integration site effects on transcrip-
tion. Nevertheless, to further minimize any confounding effect
of genome integration site by our PAC variants on subsequent
transgene expression, we decided to generate two independent
lines for each of the three genotypes. Transcription and trans-
lation of human SNCA in the mouse brain was confirmed at the
F1 generation, as shown, for example, in the Rep1-261/
261-carrying line ‘A’ in Figure 2B and C. Fluorescent
in situ hybridization (FISH) was used to determine the chro-
mosomal integration site of each line (Supplementary
Material, Table S1) and to obtain a first estimate for the
Figure 1. A schematic presentation of the PAC (27M07) used to generate the transgenic mice lines. The organization of the human SNCA locus that is included
in the PAC at the top panel. The three distinct SNCA-Rep1 genotypes are indicated below.
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range of genomic copy numbers (see, for example, 261/261
line ‘A’ in Fig. 2A). The precise copy number in each line
was then determined more accurately. To this end, we
employed quantitative real-time PCR using genomic DNA
from animals in each line by targeting two different regions
of the human PAC (29). We calculated that the relative trans-
gene copy numbers in the different lines shown here ranged
from 1 to 7 transgene copies per haploid genome (Supplemen-
tary Material, Table S1).
Next we analyzed human SNCA expression levels in the brain
and blood of F2 homozygous transgenic mice and in the hetero-
zygous D-Rep1 line ‘B’. A total of 72 F2 animals from six
mouse lines, representing two F2 lines for each of the three dis-
tinct alleles (e.g. Rep1-261 bp, Rep1-259 bp and D-Rep1 del-
etion), were sacrificed at the age of 8 weeks; these mice were
used for extended quantitative analyses at the mRNA and
protein level to determine their variation in human SNCA
expression, as controlled by each PAC transgene.
Effects of Rep1 variants on human SNCA-mRNA levels in
mouse brain
To study the effect of SNCA-Rep1 allele homozygosity on human
SNCA-mRNA levels in transgenic mouse brain (n ¼ 72), we
employed a real-time PCR assay specific for the human
message (no amplification was detected with the control WT
mouse). All levels were measured relative to the mouse synapto-
physin (Syp) endogenous reference gene by 22DCt (Fig. 3A). The
fold expression levels of each mouse line (Supplementary
Material, Fig. S1) were then corrected according to copy
number values, and the average fold expression for each of the
three transgenes was determined. Our calculations, which are
expressed as fold expression per diploid-copy of the transgene,
showed that 261/261 transgenic mice consistently generated
the highest level of SNCA-mRNA in the brain (Fig. 3B; Sup-
plementary Material, Fig. S2). Rep1 261/261 mice demonstrated
an average 0.27+0.04-fold expression level relative to that of
endogenous mouse Syp compared with an average 0.16+
0.03-fold expression level of SNCA-mRNA in the 259/259 trans-
genic lines and an average 0.08+0.06-fold expression level in
theD-Rep1 transgenic mice (Fig. 3B). From these results, we cal-
culated that the mice, which carried the PD risk-associated allele
Rep1-261 bp, harbored significantly elevated levels of human
SNCA-mRNA, amounting to a nearly 70% increase over
those mice that carried the ‘protective’ genotype, allele
Rep1-259 bp (P, 0.0001). No significant correlation was seen
between SNCA-mRNA levels in the brain and gender (P ¼ 0.44).
In addition, we aimed to study the overall effect of the
presence or absence of the Rep1 microsatellite site on the regu-
lation of SNCA-mRNA expression. SNCA-mRNA levels in the
brains of transgenic mice carrying the SNCA-Rep1 deletion
were significantly lower when compared with mice carrying
the naturally occurring alleles 261/261 and 259/259 (P,
0.0001; Fig. 3B; Supplementary Material, Fig. S2). The latter
result suggested that in the brain tissue, Rep1 might act as an
enhancer element to upregulate SNCA-mRNA levels.
Effects of Rep1 variants on human SNCA protein
concentrations in mouse brain
In parallel to these mRNA measurements, we also analyzed the
human SNCA protein content in brain homogenates of 12 age-
and gender-matched mice from each of the six lines represent-
ing the three genotypes (total n ¼ 72). We focused on the pool
of ‘soluble’ SNCA protein that are found in the neuronal cytosol
and membrane-associated compartments, which encompass
the overwhelming majority of available SNCA proteins in
young murine brain (in contrast to the low amount that is
present in ‘insoluble’ compartments at that age) (30, 31). Follow-
ing the observation of variable SNCA signals in routine western
blotting experiments (Fig. 4A), which represents a low through-
put and non-linear method of signal detection, we employed an
extensively validated, sandwich-type enzyme-linked immu-
noadsorbent assay (ELISA) protocol for the quantification of
SNCA in each mouse brain (Fig. 4B) (31–33). Using ELISA
pair [hSA3/211-B], which combines a sensitive, affinity-purified
rabbit antibody [hSA3] with a human SNCA-specific mono-
clonal antibody (mAb) (211), we first calculated the absolute
concentration (ng/ml) of human SNCA in each mouse homogen-
ate (Supplementary Material, Fig. S3A); these values were then
corrected for the gene copy number in each line to determine the
protein concentration per one diploid-copy of the transgene.
Consistent with our mRNA results, we recorded a 1.25-fold
elevation in human SNCA levels in 261/261 transgenic mouse
brain (0.71+0.30 ng/ml homogenate) over the protective
259/259 allele carrying mice (0.57+0.56 ng/ml) (P ¼ 0.0004;
Fig. 5A). As expected from the mRNA data (see above), the
Figure 2. Serial analyses to confirm the mouse lines in the study. Presented is an
example analysis performed for transgenic line ‘A’, carrying the human
SNCA-Rep1 261 bp allele. (A) FISH analysis of metaphasechromosomes obtained
from the mouse’s spleen was used to determine the insertion site and to estimate the
range of the copy number. Red-labeled human-PAC 27M07; green-labeled mouse
BAC corresponding to mouse chromosome 9, used as a reference for copy number
estimation; blue-DAPI. (B) RT–PCR to the 27M07 PAC was used to confirm the
RNA expression of the human SNCA in the brain of an F1 mouse. (C) Western blot
using the mouse monoclonal LB509 anti-human-SNCA (Zymed), to confirm the
protein expression of the human SNCA in the brain of an F1 mouse. For (B)
and (C), each lane represents analysis performed using a mouse-brain sample har-
vested from the following mouse lines: Rep1 261-A, the 261/261 line ‘A’ trans-
genic; PAC, control PAC containing the original Rep1 allele transgenic (55);
Wt, wild type FVB; hSNCA, recombinant human SNCA protein.
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lowest concentration of human SNCA was recorded in the
D-Rep-carrying mice (0.17+0.27 ng/ml) (Fig. 5A).
To control for any variability in the expression of endogen-
ous, murine snca, which could have affected transgene pene-
trance, we next calculated the relative abundance of human
versus total (i.e. human and mouse) SNCA in the same brain
homogenates. To this end, we employed our sandwich ELISA
protocol [hSA3/Syn1-B], which reproducibly quantifies total
SNCA from both rodent and primate sources and does not
cross-react with b- or with g-synuclein proteins (33)
(Fig. 4B). Mouse lines carrying the expanded Rep1-261 bp
allele showed the highest total SNCA concentration (measur-
ing human and mouse variants, i.e. 6.17+ 2.53 ng/ml hom-
ogenate), followed by lines that carry the protective
Rep1-259 bp genotype (5.63+ 4.74 ng/ml), followed by
those carrying the D-Rep1 allele (4.74+ 2.02 ng/ml) (Sup-
plementary Material, Fig. S3B). In accordance with the
above, we recorded the highest ratio of ‘human-to-total
SNCA concentrations’ following copy number corrections in
brains from 261/261 mice (average ratio 0.80), followed by
259/259 animals (average ratio 0.31) and D-Rep1 mice
(average ratio 0.13) (P, 0.0001; Fig. 5B; Supplementary
Material, Fig. S3C). The findings of relative and absolute
SNCA concentration differences between these transgenic
mouse lines remained the same when the ELISA operator
was blinded to their respective genotypes (not shown). As in
our mRNA studies before, we did not observe a
gender effect on neural SNCA protein concentrations.
We concluded from these data that the Rep1 region acts as a
cis-regulatory enhancer of SNCA transcription, thereby effec-
tively modulating the steady state of human SNCA in the
mammalian brain.
Effects of Rep1 variants on human SNCA-mRNA levels
in mouse blood
The effect of Rep1 on human SNCA-mRNA levels was also
studied in whole-blood samples from these transgenic mice
(n ¼ 72), as obtained prior to decapitation. The quantification
of SNCA proteins in peripheral blood is of interest to the PD
field as a potential biomarker (32), as well as from the perspective
of tissue-specific gene expression (34). To this end, we carried
out a similar study in mouse blood samples to the one described
above for the brain; in contrast to the brain analysis, ubiquitously
expressed Gapdh was used as the endogenous reference
probe to measure human SNCA-mRNA levels in murine
samples (Fig. 6A). We found that mice carrying the PD
risk-associated allele Rep1-261 bp showed, on average, higher
human SNCA-mRNA levels in blood specimens obtained
from the orbital sinus compared with mice transgenic for the pro-
tective genotype with allele Rep1-259 bp (0.1 versus 0.005-fold
expression on average relative to the endogenous Gapdh
mRNA levels, respectively) (Fig. 6B). However, the variability
within each genotype was quite large, and the median values
showed no significant differences (Fig. 6B). No correlation was
observed between individual blood SNCA-mRNA levels and
gender (P ¼ 0.221).
We also assessed the contributory role (if any) of the Rep1
region to SNCA-mRNA levels in these blood specimens. In con-
trast to the results obtained in brain homogenates, we did not
observe an apparent Rep1 effect on SNCA-mRNA expression
levels in these hematological specimens; there was no signifi-
cant difference in SNCA-mRNA levels in blood from mice car-
rying the deleted Rep1 allele (0.046-fold on average relative to
the endogenous Gapdh mRNA) when compared with the
average value of mice carrying either allele (261 or 259) at
the SNCA-Rep1 site (0.05-fold on average; P ¼ 0.524). Here
again, the median values did not differ among the three geno-
Figure 3. Effect of the SNCA-Rep1 promoter genotypes on human
SNCA-mRNA expression levels in transgenic mouse brains. (A) Validation
curve of the D real-time assay for relative quantization of human
SNCA-mRNA relative to mouse Syp-mRNA in the brain. Relative efficiency
plots of human-SNCA and mouse-Syp were formed by plotting the log input
amount (ng of total RNA) versus the DCt ¼ [Ct(SNCA)2Ct(Syp)]. The
slope is 0.045, which indicated the validation of the DCt calculation in the
range of 0.1–100 ng RNA. (B) Fold levels of human SNCA-mRNA were
assayed by real-time RT–PCR and calculated relative to mouse Syp-mRNA
reference control using the 22DCt method. No detectable products of the
human SNCA-mRNA reaction were observed when WT mouse brain-cDNA
was used as template. The risk genotype 261/261 correlates with significant
higher SNCA-mRNA levels than the protective genotype 259/259 (P ,
0.0001). The deleted SNCA-Rep1 genotype correlates with significant lower
SNCA-mRNA levels than genotypes 261/261 and 259/259 (P , 0.0001). In
total, 72 mice were analyzed; for each genotype (261/261, 259/259 and D/
D), the box plot represents the analysis performed using two transgenic
lines, 12 animals from each line (6 males and 6 females), comprising 24
total brain samples per genotype, each of which was analyzed twice indepen-
dently. The average values are presented by ‘X’. The box plot shows the
median (horizontal line inside the box) and the 25th and 75th percentiles (hori-
zontal borders of the box). The range between the 25th and 75th percentiles is
the interquartile range. The whiskers show the minimal and maximal values
inside the main data body.
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types (Fig. 6B). These findings suggested that the Rep1 element
did not appear to regulate the expression level of SNCA gene in
the hematological precursor cells that generated these blood
specimens (34,35), thereby suggesting a neuro-specific effect
for the Rep1 element (27).
In order to determine whether SNCA-mRNA levels in the
blood are individually concordant with mRNA levels recorded
in the brain, we carried out several correlation studies in these
mice; however, the comparison of the relative SNCA-mRNA
levels between the brain and blood samples from each individ-
ual animal showed no correlation.
Effects of Rep1 variants on human SNCA protein
concentrations in mouse blood
We next analyzed the effect of Rep1 on human SNCA protein
levels in sister aliquots of the same blood specimens from trans-
genic mice carrying these three different alleles. To this end, we
examined blood lysates from age- and gender-matched mice by
the same two ELISA protocols employed above (Supplementary
Material, Fig. S4A) and corrected the SNCA signal for the gene
copy number in each animal. The parallel analysis of blood
lysates (n ¼ 72) on the same ELISA plate by an operator
blinded to the genotype revealed no statistically significant
difference in the levels of human SNCA (P ¼ 0.477) among
the six transgenic lines that carried the three distinct
SNCA-Rep1 genotypes (Fig. 7A). In accordance with the
human-specific values, the total SNCA concentration (of
human and mouse SNCA) in these blood specimens did not
reveal a significant difference in the Rep1-261 bp-carrying
animals (Rep1-261 bp; total SNCA 20.68+ 2.96 ng/ml) when
compared with the other two genotypes (Rep1-259 bp
19.59+ 3.14 ng/ml; D-Rep1 18.60+ 2.33 ng/ml) (Supplemen-
tary Material, Fig. S4B). After copy number correction, the total
SNCA concentration in the mouse blood showed a trend for the
reduction in the PD risk-associated Rep1-261 bp animals, but
the variability, in particular within the Rep1-259 bp genotype,
was large (Fig. 7B). The calculated ratios of ‘human-to-total-
SNCA levels following gene copy number correction’ were
0.85 in 261/261 mice, 1.23 in 259/259 animals and 1.28 in
D-Rep1 mice. However, it is important to state that the overall
human SNCA protein concentrations in these mouse blood
Figure 4. Analyzing SNCA proteins in F2 transgenic mouse brains. Representative western blotting (A) and ELISA (B) results from 24 age- and gender-matched
F2 transgenic mouse brains are shown for the three distinct genotypes in six mouse lines. Specimens were assayed with a combination of polyclonal (pAb) and
monoclonal (mAb) anti-SNCA antibodies. Equal volumes of whole-brain extracts were either directly loaded onto reducing SDS–PAGE (A) or first adjusted for
their total protein content, then diluted at 1: 5000 and subsequently loaded onto ELISA plates (B). Sandwich ELISA (hSA-3/211-B; red bars to the right of each
pair) and ELISA (hSA-3/Syn1-B; blue bars on the left of each pair) were carried out on the same 384-well plate in triplicates. Note the near identical monitoring
of the recombinant human SNCA protein standards by both assays (left); the absence of any absorbance signal in snca-null (KO) mouse brain by either assay and
the absence of signal with the human SNCA-specific ELISA in WT (non-transgenic) mouse brain (center); the fact that the total SNCA signal measuring murine
and human protein (blue bars, left) is always stronger than the human-specific signal alone (red bars, right).
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specimens were markedly lower than in comparable human
specimens (34,35), which may explain the failure to detect
any consistent and meaningful variations. These results
suggested that the human SNCA protein levels in these blood
specimens did not parallel the expression levels found in the
brains from the same mice.
DISCUSSION
This study describes a novel approach in the field of neurode-
generative diseases for examining the role of genetic variations
positioned in non-coding, putative regulatory regions of the
human genome by aiming to identify causality for regulatory
variants. Gene expression studies in humans, especially when
they involve the analysis of post-mortem brain, often introduce
several confounding variables, e.g. differences in genetic
background, age, environmental exposures (including pharma-
cotherapy), length of illness and importantly, variability in post-
Figure 5. SNCA-Rep1 expansion increases SNCA protein concentration in
mammalian brain. (A) Quantification of human SNCA protein in transgenic
mouse brain homogenates using sandwich ELISA [hSA-3/211-B] and a
384-well plate format (triplicates; 50 ml/well); a total of 72 mice were analyzed.
Concentration values (in ng/ml) were interpolated from the standard curve (Sup-
plementary Material, Fig. S3A) and then corrected for the calculated gene copy
number in each mouse line. Values were grouped according to the three geno-
types examined, i.e. Rep1-261 bp; Rep1-259 bp; D-Rep1 (ratio: female:male,
50:50 in all lines). (B) Relative ratio of the human SNCA concentration (as
shown in A) to the total SNCA protein concentration. The latter was measured
using sandwich ELISA [hSA3/Syn1-B] on 384-well plates quantifying both
mouse Snca and human SNCA (Supplementary Material, Fig. S3B; after correc-
tion for gene copy number: Supplementary Material, Fig. S3C). Bar graph
shown in (B) represents values obtained in (A) divided by those shown in Sup-
plementary Material, Fig. S3C.
Figure 6. Effect of the SNCA-Rep1 promoter genotypes on human
SNCA-mRNA expression levels in transgenic mouse whole blood. (A) Vali-
dation curve of the D real-time assay for relative quantization of human
SNCA-mRNA relative to mouse Gapdh-mRNA in blood. Relative efficiency
plots of human-SNCA and mouse-Gapdh were formed by plotting the log
input amount (ng of total RNA) versus the DCt ¼ [Ct(SNCA)2Ct(Gapdh)].
The slope is 0.1, which indicated the validation of the DCt calculation in
the range of 0.1–100 ng RNA. (B) Fold levels of human SNCA-mRNA
were assayed by real-time RT–PCR and calculated relative to mouse
Gapdh-mRNA reference control using the 22DCt method. No detectable pro-
ducts of the human SNCA-mRNA reaction were observed when WT mouse
blood-cDNA was used as template. The risk genotype, 261/261, correlates
with higher SNCA-mRNA levels than the protective genotype, 259/259. The
deleted SNCA-Rep1 genotype shows no significant correlation with
SNCA-mRNA levels in comparison with genotypes 261/261 and 259/259
(P ¼ 0.524). In total, 72 mice were analyzed; for each genotype (261/261,
259/259 and D/D), the box plot represents the analysis performed using two
transgenic lines, 12 animals from each line (6 males and 6 females);
overall, 24 whole-blood samples (per genotype) were each repeated twice,
independently. The average values are presented by ‘X’. The box plot
shows the median (horizontal line inside the box) and the 25th and 75th per-
centiles (horizontal borders of the box). The range between the 25th and 75th
percentiles is the interquartile range. The whiskers show the minimal and
maximal values inside the main data body.
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mortem interval and tissue handling. All of these factors can
affect mRNA and protein stability, and thus their measureable
abundance (36,37). In order to overcome the combination of
these confounding factors involved in studying mRNA and
protein levels in human post-mortem tissue, we took the
novel approach of studying human gene expression in a trans-
genic mouse model. Transgenic mouse models have been
used, almost exclusively, to study the effect of mutations in
coding gene sequences. Here, we generated a transgenic
model, which carries the entire human genomic region of the
SNCA gene, to study the effect of a variation located 10 kb
upstream of the transcription start site within the putative pro-
moter/enhancer region and to dissect its contribution to
human SNCA expression levels in vivo.
A critical question concerning the molecular pathogenesis
of PD is what contributory role, if any, is played by the
SNCA gene in sporadic PD. Several studies conferred an
association of common SNCA polymorphisms in the 50 and
30 regions of the gene locus with PD susceptibility (16–19)
(38); however, the causal variant/s and hence the underlying
mechanism/s remained elusive. We hypothesized that altered
regulation of SNCA gene expression levels is important in
the development of sporadic PD in a significant subset of
patients; these include subjects who do not express a mutant
SNCA protein and who do not carry an elevated SNCA gene
dosage in their genome. One important mechanism that modu-
lates gene expression levels is transcriptional efficiency.
Markers across the 50 region of SNCA that were associated
with increased odds ratio to develop PD are in almost com-
plete linkage disequilibrium with each other, which makes
pinpointing the biologically relevant variant within an associ-
ated 50 region challenging. In this study, we provide evidence
for a contributory role of the SNCA-Rep1 variant in the tran-
scriptional regulation of the SNCA gene and in their effects
on SNCA-mRNA and protein levels in mouse brain. We
found a positive correlation between SNCA-Rep1 allele
lengths at the SNCA enhancer/promoter region and human
SNCA-mRNA as well as protein levels in the brains of these
transgenic mice. Although we are cognizant of the potential
limitations by using whole-brain homogenates rather than
region-specific specimens (that are of relevance to PD patho-
genesis), we purposefully sought to minimize any introduction
of inaccuracies stemming from variability in tissue dissection
and to accommodate a larger number of animals in our quan-
titative assays. Our results show that allele Rep1-261 bp,
which confers increased risk to develop late-onset, sporadic
PD, was significantly correlated with higher SNCA levels rela-
tive to the protective allele Rep1-259 bp (P , 0.0001). Intri-
guingly, our collective data suggest that the carrier status of
Rep1-261 bp homozygosity within an otherwise WT comp-
lement of two SNCA gene copies results in a 1.7-fold elevation
of SNCA-mRNA and a 1.25-fold elevation in the protein level,
suggesting that variability in translational efficiency had only
a limited effect. Therefore, Rep1-261 bp homozygosity may
be functionally equivalent to the situation of subjects with
SNCA locus duplication who carry three SNCA copies, which
results in 1.5-fold elevation. We therefore speculate that
Rep1-261 bp homozygosity confers a critical gain-of-function
mechanism in PD penetrance and in the expressivity of synu-
cleinopathies (6).
Although the biological effect of the Rep1 expansion was
observed in the most relevant organ to PD expression, i.e.
the brain, its contribution appeared specific because its
enhancer role was not recorded in the corresponding blood
specimens. Of note, Fuchs et al. (28) recently reported a
positive genotype-to-phenotype effect for Rep1 repeat
length in human blood samples, where homozygotes of the
protective, shorter allele had lower concentrations of
SNCA protein in peripheral blood mononuclear cells; intri-
guingly, and in agreement with our finding, these authors
observed no effect at the mRNA level in peripheral blood.
At the current time, we cannot exclude a modulatory
effect by the Rep1 genotype on SNCA protein levels in per-
ipheral blood (as suggested by Fuchs et al.), because the
Figure 7. SNCA-Rep1 expansion does not lead to detectable SNCA protein
concentration differences in mouse blood. (A) Quantification of human
SNCA protein in transgenic mouse blood homogenates using sandwich
ELISA [hSA-3/211-B] and 384-well plate format (triplicates; 50 ml/well); a
total of 72 mice were analyzed. Signals were specific for human SNCA
protein because whole blood from WT and snca-knockout mice did not gen-
erate ELISA signals above the background (Supplementary Material,
Fig. S4A). Values were then corrected for the calculated gene copy number
in each mouse line and grouped according to the three genotypes examined,
i.e. Rep1-261 bp; Rep1-259 bp; D-Rep1 (ratio: female:male, 50:50 in all
lines). (B) Quantification of total SNCA protein concentration levels in trans-
genic mouse blood was carried out with sandwich ELISA [hSA3/Syn1-B] and
384-well plates. This ELISA measures both mouse snca and human SNCA
proteins (Supplementary Material, Fig. S4B); values (in ng/ml) were then cor-
rected for gene copy number.
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human protein concentrations in our transgenic mouse blood
were unexpectedly low, which could have put any significant
variation below the limit of detection. The discrepancy
between the Fuchs et al. and our study may also be
explained by a variety of other factors; chief among them
are the differences in donor species and sample sizes, the
methods of blood collection and processing and, last but
not least, the differences between the ELISA protocols
employed.
The quantification of peripheral SNCA-mRNA levels
together with the characterization of the Rep1 genotype has
also been explored in the context of alcohol use-related dis-
orders (39); the most recent study suggests an independent
(but not a pairwise) association of Rep1 genotype and
alcohol abuse with PD risk (40). Clearly, larger cross-sectional
and longitudinal studies of carefully collected cohorts and
validated, standardized protocols are now needed to further
investigate these neuropsychatric conditions. This aspect is
particularly relevant for PD biomarker efforts that seek to cor-
relate variations in the transcriptome and/or proteome of
venous blood with the clinical phenotype of living donors
(11,41). Overall, the observed neuro-specific effect of the
Rep1 element in vivo using a mouse model is consistent
with our previous cellular results. Using a luciferase reporter
system, we had observed that the construct harboring the
expanded allele at the SNCA-Rep1 site generated the highest
luciferase activity specifically in dopaminergic SH-SY5Y neu-
roblastoma cells (27).
Our results lend support for the overall biological signifi-
cance of SNCA-Rep1, thereby suggesting that many of the
observed associations between the SNCA 50 region and PD
susceptibility could possibly be explained by variations in
SNCA-Rep1 genotype. We predict that the association of the
261 bp-long risk allele with sporadic PD is conferred by
direct upregulation of SNCA transcription, and that the protec-
tive allele 259 bp acts through the lowering of its expression
rate. Here, we chose to focus on the two most common
Rep1 alleles; we acknowledge the role that other variants
may play, such as the rare PD-associated 263 bp-long Rep1
variant (25). Additional Rep1 allelic variants will be analyzed
using newly created transgenic mice in future studies. Likewise,
it will be of interest to determine whether our PAC mice will
develop any neuropathological and behavioral features of
human synucleinopathies toward the end of their lifespan that
are currently not seen in those transgenic models that are
based solely on an SNCA cDNA construct design (42,43). At
the age of 8 weeks, we have observed no readily recognizable
alteration in the behavior of the mice used in this study.
In our previous work, we identified a transcription factor,
poly(ADP-ribose) transferase/polymerase-1 (PARP-1, MIM
173870), which specifically bound to Rep1 and modulated
SNCA transcription (44). It will be interesting to explore
whether the variability in SNCA regulation (as mediated by
Rep1 alleles) rests on altered binding efficiency of PARP-1
to Rep1 sequences that vary in length. Alternatively, our
observed Rep1 expansion effect could also be explained by
interaction/s with cis-acting elements during chromatin
unfolding, which precedes SNCA gene transcription, for
example, with the recently discovered GATA motif within
intron 1. This intronic GATA site is selectively occupied by
GATA-2 (MIM 137295) protein in neurons and by GATA-1
(MIM 305371) in erythroid cells (34).
The transgenic mouse approach we have pursued here could
serve as a valuable model system for a variety of future studies
in the PD field, including those that examine gene–environment
interactions, such as the protective effects of smoking (45,46);
our approach may also serve proof of concept studies, such as
those that target the reduction of human SNCA levels in vivo
either through the specific modulation of mRNA translation
(47) or through the acceleration of SNCA degradation by candi-
date enzymes (33,48). The unequivocal evidence that puts
increased steady states of SNCA at the center of PD develop-
ment (10,11,47,49,50) emphasizes the importance of studies
like ours in the pursuit of three important (and related) research
goals: to better dissect the pathogenesis of synucleinopathies; to
develop earlier markers of risk and disease state; and to find
validated drug targets near the root of Parkinson’s to initiate
cause-directed therapy in the future. Further exploration of
the mechanism by which Rep1 allele expansion enhances
human SNCA gene transcription in at-risk neurons may serve
all three goals.
MATERIALS AND METHODS
Recombineering PAC
A PAC containing the 146 kb PAC 27M07 (RPCI human male
PAC library, BAC/PAC Resource Center, Children’s Hospital,
Oakland, CA, USA) was used as the substrate for recombi-
neering by the method of Lee et al. (51). Human genomic
DNA spanning the SNCA-Rep1 locus and containing either
the 261 bp allele ((TC)10(T)2(TC)10(TA)8(CA)11, heretofore
referred to as Rep1-261 bp) or the 259 bp allele ((TC)10(T)2
(TC)10(TA)8(CA)10, heretofore referred to as Rep1-259 bp)
was isolated by PCR of anonymous human DNA of the appro-
priate SNCA-Rep1 genotype (Centre d’Etude du Polymor-
phisme Humaine). Alleles were defined according to the
length of the PCR product in concordance to the conventional
nomenclature (20,25). The PCR fragments were sequenced
and then cloned into a recombineering vector for site-directed
recombination in Escherichia coli into the SNCA-Rep1 locus
in PAC 27M07. A third PAC was recombineered in which
the SNCA-Rep1 repeat had been precisely deleted, heretofore
referred to as D-Rep1 (27). All three PACs were identical
except at the SNCA-Rep1 locus.
Generation of transgenic lines
The three different constructs were microinjected into the pro-
nuclei of fertilized FVB/N mouse ova by standard techniques.
F1s heterozygous for the intact human PAC transgenes were
crossed to produce homozygotes for each allelic variant trans-
gene. Mice homozygous for the human transgene harboring
261 and 259 bp SNCA-Rep1 alleles and the deleted allele are
referred to as 261/261, 259/259, D/D mice, respectively. Of
note, one of the D-Rep1 lines, ‘B’, was non-viable probably
due to insertion site effect, thus for this line, the analysis
was performed using heterozygous mice, and the transgene
copy number was corrected accordingly (see below). Two
lines were generated from each genotype (i.e. a total of six
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lines). Six male and six female F2s homozygous from each
transgenic line, 72 mice in total, were sacrificed at the age
of 8 weeks for sample collection. Blood was collected from
the orbital sinus, and subsequently, the whole brain was har-
vested. It is important to note that all mouse lines shared an
identical genetic background, which included the WT
murine snca locus, and were reared in the same environment.
In addition, all of the mice underwent identical blood collec-
tion and brain-harvesting procedures.
DNA analysis of transgenic mice
We used DNA from mouse tails to confirm the founders. The
SNCA-Rep1 genotypes were verified by direct sequence analy-
sis of the polymorphic repeat and its flanking region. The
intactness of the PAC transgenes in each founder animal and
its transmission to the F1 generation were assayed by a
routine series of 10 PCR assays along the transgene sequence.
Primer sequences and PCR conditions for genotyping are
available upon request. FISH was used to estimate transgene
copy number in the F1 generation. Briefly, the human-PAC
targeting construct and a mouse BAC covering comparable
size sequence from mouse chromosome 9 were used as
probes. Interphase preparations from leukocytes and meta-
phase preparations from spleen cells were generated by stan-
dard air-drying technique, and FISH was performed with
labeled DNA prepared by nick translation using spectrum
orange-dUTP (red) or spectrum green-dUTP (green) (Vysis,
Downers Grove, IL, USA) essentially as described previously
(52,53). On each slide, 100 ng of labeled probe was applied.
Ten microliters of a hybridization mixture containing the
labeled DNA in 50% formamide, 2 SSC and 10% dextran
sulfate were denatured at 758C for 10 min and then incubated
at 378C for 30 min for preannealing. Slides were denatured
and hybridized for at least 18 h and counterstained with
DAPI–Antifade before viewing. The relative number of the
transgene-DNA copies was estimated by comparison of the
signal intensity from the transgenic versus the endogenous
probes.
Routine genotyping of all the newborn (F1 and F2 gener-
ations mice) was performed by PCR with one of the primer
sets used in the founder analysis. To differentiate between
F2 homozygous and heterozygous animals, we performed
FISH analysis as described above.
Determination of the relative transgene copy number
To assay for transgene dosage, genomic DNA was extracted
from F1 mice liver by standard Qiagen protocol and quantitat-
ive real-time PCR targeting two different regions along the
human PAC, i.e. human-SNCA exons 2 and 6, was performed
on the ABI Prism 7900 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). The b-actin gene was
amplified as an endogenous reference for the quantification
of the human-SNCA transgene using ABI MGB probe and
primer set assay-by-demand ID Mm00607939_s1 (Applied
Biosystems). The assay-by-design primers and probes
sequences for SNCA exon 2 and exon 6 were described pre-
viously (29). TaqMan MGB probes for human SNCA exon
2, exon 6 and mouse b-actin were labeled with 6-FAM.
PCR was carried out with TaqMan Universal PCR Master
Mix using 10 or 50 ng genomic DNA, 900 nM primers and
250 nM probes in a total reaction volume of 20 ml. The reac-
tions for the test SNCA loci and the reference b-actin locus
were prepared and run in parallel. PCR cycling conditions
were as follows: 958C for 10 min, 958C for 15 s and 608C
for 1 min (40 cycles). Each genomic DNA sample was
assayed in two different gDNA amounts (10 and 50 ng),
running each amount in duplicate and the entire assay was
repeated twice. The cycle in the log phase of PCR amplifica-
tion at which a significant fluorescence threshold was reached
(Ct) was used to quantify each exon. For each transgenic line,
the dosage of PAC transgene relative to b-actin and normal-
ized to control DNA was determined for each exon using
the 22DDCt method. A value was considered as a single copy
if it was within the range of 0.8–1.2. Greater copy numbers
were calculated as ratios relative to a single copy value. A
standard curve was generated using gDNA 0.1, 1, 10, 25,
50, 100 and 150 ng, and a regression curve was calculated
for each assay (exon 2 and exon 6). In addition, the slope of
the relative efficiency plot for SNCA exons 2 and 6 and the
reference control b-actin was determined to validate the
assays (Supplementary Material, Fig. S5). The transgene
copy number was calculated relative to the endogenous
mouse b-actin (Act) gene, and all copy number variations
were expressed relative to having one copy number per
haploid genome (ratio of 0.8–1.2 for homozygous transgene
relative to diploid mouse b-actin gene). The copy number of
the only heterozygous D-Rep1 transgenic line ‘B’ was
adjusted accordingly.
RNA extraction and cDNA synthesis
Total RNA was extracted from half whole brain and whole
blood (200 ml) using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) followed by purification with RNeasy Kit
(Qiagen, Valencia, CA, USA) following the manufacturer’s
protocol. RNA concentration was determined spectrophotome-
trically at 260 nm, and the 260/280 nm ratio determined the
quality of the purification. In addition, the quality of the
sample and the lack of significant degradation products were
confirmed on an Agilent Bioanalyzer. Next, cDNA was syn-
thesized using MultiScribe RT enzyme (Applied Biosystems)
under the following conditions: 10 min at 258C and 120 min
at 378C.
RT–PCR and real-time PCR
The expression of SNCA-RNA in the brain tissues of F1 gen-
eration mice was determined for each line by RT–PCR using
the forward primer 50-CATGGATGTATTCATGAAAGG-30
and reverse primer 50-GAGTGTAGGGTTAATGTTCC-30.
Real-time PCR was used to quantify human SNCA-mRNA
levels in F2 generation transgenic mice as described pre-
viously (14). Briefly, duplicates of each sample were
assayed by relative quantitative real-time PCR using the
ABI 7900 for the analysis of the level of SNCA message
when compared in brain tissues to mRNA-encoding mouse
synaptophysin (Syp), a presynaptic protein that has similar
expression pattern to SNCA, and in blood to the mouse ubiqui-
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tous gene, glyceraldehyde-3-phosphate dehydrogenase
(Gapdh), as internal references (14,44). Each cDNA (10 ng)
was amplified in duplicate using TaqMan Universal PCR
master mix reagent (Applied Biosystems) and the following
conditions: 2 min at 508C, 10 min at 958C, 40 cycles: 15 s at
958C, and 1 min at 608C. The target SNCA cDNA was ampli-
fied using ABI MGB probe and primer set assay ID
Hs00240906_m1, normalized to a Syp RNA control (ABI
MGB probe and primer set assay ID Mm00436850_m1) for
the brain samples and to a Gapdh RNA control (ABI MGB
probe and primer set assay ID Mm99999915_g1) for the
blood samples (Applied Biosystems). As a negative control
for the specificity of the human-SNCA ‘assay-on-demand’
amplification of human message, we used whole-brain and
blood RNA samples from WT FVB mouse. Data were ana-
lyzed with a threshold set in the linear range of amplification.
The cycle number at which any particular sample crossed that
threshold (Ct) was then used to determine the fold difference.
Fold difference was calculated as 22DCt; DCt¼ [Ct(SNCA)2
Ct(Syp or Gapdh)]. Of note is that three internal controls were
compared: mouse glyceraldehyde-3-phosphate dehydrogenase
(Gapdh Mm99999915_g1), mouse alpha-synuclein (Snca
Mm00447331_m1), mouse enolase 2 (Eno2 Mm00469062_m1)
and synaptophysin (Syp Mm00436850_m1) using different
total RNA amounts (0.1–100 ng) from whole-brain tissue and
whole-blood samples of a transgenic mouse. For assay validation,
we used standard curves for each assay (Gapdh, Snca, Eno2 and
Syp) using a transgenic mouse whole-brain and whole-blood
RNA samples. In addition, the slope of the relative efficiency
plot for SNCA and each internal control was determined to vali-
date the assays. The slope in the relative efficiency plot for
mouse Syp and human SNCA in brain (0.045) and for mouse
Gapdh and human SNCA in blood (0.1) were the smallest,
showing a standard value required for the validation of the relative
quantitative method (Figs 3A and 6A). Thus, for the extended
study, we chose Syp and Gapdh as the internal control for the
whole brain and blood, respectively. In addition, for a subset
group of brain samples, we used the geometric mean of mouse
Syp and Eno2 as a normalization control and confirmed the
selection of Syp as a representative normalization control for
the entire brain set.
Western blotting and antibodies
The expression of human SNCA protein in the brain tissues
was determined by western blotting with the mouse mAb
LB509 (Zymed) and mAb 211 that are specific for the
human orthologue of SNCA, with mAb Syn-1 (Transduction
Labs) and hSA3. The latter is a polyclonal Ab raised and
affinity-purified against full-length, human SNCA, as
described (33). Syn-1 and hSA3 Ab react with both the
mouse and human orthologues of SNCA (31).
Whole brains from 2- to 3-month-old mice were homogen-
ized in 10-fold volume of 50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% Nonidet P-40, in the presence of a protease inhibitor
cocktail (Sigma, St Louis, MO, USA) using a hand-held
motorized pestle. After centrifugation to remove particulates
at 100 000g (30 min; 48C), total protein concentrations were
determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules,
CA, USA), and 20 mg of each sample was run on 15% Tris–
glycine SDS–PAGE. Proteins were transferred to PVDF
membranes (Immobilon-P, Millipore, Bedford, MA, USA),
and blots were blocked with 2% casein in 0.1 M Tris, 0.2 M
NaCl, pH 9.5. Secondary antibody was horseradish
peroxidase-coupled goat anti-mouse IgG (Amersham,
Chicago, IL, USA), used at 1:10 000. The immunoreactive
proteins were detected using the ECL system (Amersham)
according to manufacturer’s instructions. For the analysis of
F1 generation mouse lines, transgene expression was deter-
mined by western blots in comparison with recombinant
human SNCA (50 ng).
Enzyme-linked immunoadsorbent assays
SNCA protein levels were assessed using a 384-well-based
sandwich ELISA system as described recently in detail (33,
34). For specific quantification of the human orthologue, we
employed the Ab sandwich [hSA3/211-B]; for the quantifi-
cation of total SNCA (i.e. mouse and human combined), we
employed the sandwich pair [hSA3/Syn1-B], where ‘B’
stands for biotinylation). Recombinant protein was used in
standard dilutions for the interpolation of SNCA concen-
tration, as described (33). ELISA signals were monitored at
405 nm every 5 min for up to 60 min. Saturation kinetics
were examined for the identification of time point(s) where
standards and sample dilutions were in the log phase (33).
To control inter-assay variability, all samples were run using
two different dilutions in triplicate on the same day with the
same lot of standards. Also, a mouse WT versus knock-out
Snca curve was generated and included as positive and nega-
tive control for the [hSA3/Syn1-B] assay (33); both WT and
knock-out snca mouse tissue served as negative controls for
the human SNCA-specific [hSA3/211-B] assay. The relative
concentration estimates of human SNCA in transgenic
mouse brain and blood specimens were calculated according
to the standard curve. Frozen mouse brains were thawed,
weighed (mg), individually homogenized in three volumes
(ml) of Triton X-100-containing lysis buffer and centrifuged
at 100 000g during 30 min at 48C, as described (54). Note
that each round of homogenization included at least one repre-
sentative from each of the two mouse lines of the three geno-
types. Protein concentrations were calculated and equalized
prior to loading. Frozen whole-blood specimens from decapi-
tated mice (drawn in EDTA-containing tubes) were thawed,
diluted with normal saline-containing Triton X-100 (1%) and
protease inhibitors (Roche) and centrifuged before ELISA
analysis.
Statistical analysis
SNCA-mRNA fold expression value of each sample was ana-
lyzed repetitively and the results of all replicates were aver-
aged. The average values for each sample (12 samples per
line) were used to calculate the average fold expression of
each of the six lines. All average values were expressed as
mean+SEM. The significance of the difference between the
mRNA measurements of the three strains carrying the differ-
ent SNCA-Rep1 alleles was analyzed by the one-sided Wil-
coxon rank-sum test. Correlations were assessed by linear
regression analyses. The general linear model (GLM)
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method was used to evaluate the effect of the primary
explained variable (SNCA-Rep1 genotype) as well as other
secondary variable (sex) on the RNA levels. The GLM is a
procedure unifying the ordinary linear regression and
ANOVA as well as other procedures based on the least
square computation such as ANCOVA. Since gender may
also show an effect on the RNA levels, it was included in
the model as a factor. Where the P-value of the maximal
model remains significant, an effect of each single term was
estimated calculating the type III sum of squares and the cor-
responding F-value and its P-value. Protein concentrations of
all mice from each line were used to calculate the average
protein concentration of human SNCA of each of the six
lines, which were expressed as mean mean+SEM. All ana-
lyses were carried out using STATA/IC10.0 statistical soft-
ware (StataCorp, College Station, TX, USA).
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